Key facts
- It has raised $3.0M; the latest was Seed Round in Dec 2024.
- Notable investors include National Institutes of Health, Mark Armenante, National Institute for Allergy and Infectious Disease, National Institutes of Arthritis and Musculoskeletal Diseases, U.S. Department of Health and Human Services — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Oryn Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Oryn Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oryn Therapeutics
Developer of a novel class of macrocyclic peptides designed to restore immune balance in autoimmune and chronic inflammatory diseases. The company offers small, engineered, cell-permeable, and stable cyclic peptides with low immunogenicity and unique target engagement, enabling patients with autoimmune and inflammatory conditions to benefit from potent and safe therapies.
- Sector
- Healthcare
- HQ
- West Hollywood, CA, United States
- Founded
- 2013
- Employees
- 3
- Website
- oryntherapeutics.com/
- Ownership
- Privately Held (backing)
Oryn Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oryn Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oryn Therapeutics in its N-PORT filings yet. We sweep new filings monthly.